Frontotemporal DementiaPhase 2Nabilone-FTDNCT05742698
Nabilone for Agitation in Frontotemporal Dementia
A Phase 2 study testing Nabilone in people with Frontotemporal Dementia and Frontotemporal Dementia, Behavioral Variant, run by Simon Ducharme, MD at 7 sites in Canada.
Trial summary
The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant, Primary Progressive Aphasia
- What is being tested?
- Nabilone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3 participants
- Where
- 7 sitesCanada
- Study dates
- 7 Mar 2023to 31 Dec 2025
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women over 18 years
- Major neurocognitive disorder due to probable behavioural variant FTD (Rascovsky criteria)17 or primary progressive aphasia (Gorno-Tempini criteria)18. All ages and severity levels will be included.
- Meets International Psychogeriatric Association criteria for agitation in cognitive disorders19
- CMAI score of 39 or above
- Stable psychoactive medication for 2 weeks prior to screening (all medications allowed) with no intention to change dose during treatment period
- Available study partner with ≥10 hours per week in-person contact with the patient. This can either be a friend/family member or a staff member at an assisted living facility.
- Capacity to provide written consent in English or French, or consent from official surrogate decision maker in case of incapacity
- Rationale for Inclusion Criteria: The inclusion criteria are designed to enroll patients with FTD with the behaviours of interest, with a range of disease severity that will permit assessment of all outcome measures.
Who cannot join
- Clinically significant psychotic symptoms (Neuropsychiatric Inventory domain score (severity x frequency) ≥4 on the delusions or hallucinations subscale)
- Clinically significant orthostatic hypotension (a decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within three minutes of standing compared to blood pressure in a seated position)
- Symptomatic orthostatic tachycardia (heart rate increase from of at least 30 beats per minute within the first 5 minutes of standing compared to a seated position IF orthostatic hypotension is not a problem)
- Unstable cardiovascular condition in the opinion of the investigator
- Known or suspected history of drug or alcohol dependence or abuse in the past 12 months, including use of any psychomimetic drugs (e.g. ketamine, lysergic acid diethylamide, psilocybin).
- Allergy, or significant adverse reaction to cannabinoids. If the adverse reaction involved psychological symptoms that are indicative of psychosis or severe anxiety the patient will be excluded. Their treating clinician may be consulted for a clinical opinion on the severity of the response to cannabis and whether this justifies exclusion from the trial.
Show all 12Show fewer
- Major depressive episode within 6 months of screening
- Women who are breast feeding or pregnant
- Severe liver dysfunction, as determined by their treating clinician
- Other psychiatric or neurological condition that could cause significant agitation
- Ongoing use of any cannabinoid-related products. This includes any THC or CBD based products, regardless of administration method (oral, inhalation, topical, etc…)
- Rationale for Exclusion Criteria: The exclusion criteria are designed to avoid inclusion of patients who may have medical comorbidities that would increase their risk of serious side effects from repeated nabilone administration.
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
Canada7 sites
CHU de Québec, Université Laval
Laval, Quebec, G1V0A6
Brain and Mind Institute, University of Western Ontario
London, Ontario, 2P6H+GJ
The Douglas Research Centre
Montreal, Quebec, H4H1R3
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N3M5
Baycrest Hospital, University of Toronto
Toronto, Ontario, M6A2E1
Western Hospital - University of Toronto
Toronto, Ontario, MH3V+9R
University of British Columbia, St Paul's Hospital
Vancouver, British Columbia, V6Z1Y6
About this study
Official title: Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia
The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.
Read the detailed description
While the search for disease modifying treatment of frontotemporal dementia (FTD) remains elusive, on a day-to-day basis, clinicians struggle to help manage the severe neuropsychiatric symptoms of FTD. Agitation, irritability and aggression are common features of the behavioral variant of FTD and to a lesser extent in primary progressive aphasia, and these symptoms are strongly linked to care partner burden. Unfortunately, current pharmacological options for neuropsychiatric symptoms have limited efficacy. Agitation, aggressive behaviors and irritability in FTD are usually pharmacologically managed with a trial-and-error approach using a combination of trazodone, selective serotonin reuptake inhibitors, antiepileptic drugs, memantine and frequently, antipsychotics. Unfortunately, current pharmacological treatment options for neuropsychiatric symptoms of FTD have limited efficacy and are often based on small case studies or anecdotal evidence. Trazodone has the most support from randomized control trials, but shows limited effectiveness. Therefore, in clinical practice second-generation ('atypical') antipsychotics are commonly used despite a paucity of scientific evidence in FTD. This practice is problematic as antipsychotic use in dementia bears a significant burden of side-effects, including falls, and increased cerebrovascular accidents and mortality. There is a clear need for new treatments using novel mechanisms for neuropsychiatric symptoms in FTD.
One promising candidate is nabilone, a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of FTD. We propose to conduct the first randomized clinical trial of nabilone for agitation, irritability, and aggression in FTD to obtain data on real-life effectiveness and tolerability. There is a need to obtain data on the efficacy of nabilone on a wide variety of neuropsychiatric symptoms beyond agitation in FTD, while also ensuring the safety of the medication (e.g., is there a detrimental effect on apathy and hyperorality, which are common in FTD). We require data on dosing and tolerability in this population, which is younger on average than Alzheimer's disease subjects from previous studies and therefore may tolerate higher doses of nabilone. The objective of this trial is to obtain robust evidence for the effectiveness and tolerability of nabilone in FTD.
- Conditions
- Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant, Primary Progressive Aphasia, bvFTD, PPA, FTD
- Being tested
- Nabilone, Placebo
- Keywords
- Nabilone, Nabilone FTD, Agitation, TEVA Nabilone, Dementia, BvFTD, FTD
- Medical subject headings
- Frontotemporal Dementia, Pick Disease of the Brain, Aphasia, Primary Progressive, Psychomotor Agitation, Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NabiloneDrug
Also called Nabilone Oral Capsule, TEVA Nabilone
Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
PlaceboDrug
The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
| Study group | Role | What they receive |
|---|---|---|
| Nabilone | Active comparator | Weeks 1-2 Nabilone and placebo will be taken orally by the patient as per the schedule provided by the research team. All patients will start with one 0.5mg capsule per day, taken before bed for the first week and then increase administration to the 1mg capsule taken before bed for the second week.
Weeks 3-4 Two weeks after the start of the trial patients and study partners will attend an in person or remote Interim Assessment. If remission is not achieved and no clinically significant adverse drug reactions are reported then the dose schedule will increase to 2 capsules per day (2mg/day), 1 capsule in the morning and 1 before bed.
Weeks 5-6 Four weeks after the start of the trial there will be a second in person or remote Interim Assessment identical to the first. If remission of agitation has not been achieved and no adverse drug reactions are reported the dose schedule will increase to 4 tablets per day (4mg/day), with 2 tablets in the morning and 2 before bed. Receives: Drug: Nabilone |
| Placebo | Placebo comparator | Weeks 1 and 2 Participants will receive one capsule per day to be taken orally before bedtime.
Weeks 3-4 Participants will receive 2 capsules per day, one in the morning and one before bedtime.
Weeks 5-6 Participants will receive 2 capsules per day, one in the morning and one before bedtime.
The placebo dosing regimen is designed to be as similar as possible to the nabilone dosing regime, including using identical capsules. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cohen Mansfield Agitation Inventory (CMAI)
A scale that is completed by a caregiver with at lest 10 hours of weekly contact with the patient. This scale evaluates a range of symptoms that fall into the category of agitation.
Measured: The patients CMAI score will be compared between their Baseline Assessment (prior to starting treatment) and the outcome Assessment (after 6 weeks of treatment) to determine whether agitation has changed across the treatment period.
Secondary outcomes (2)
Tumor necrosis factor alpha (TNFα)
Examine the relationship between TNFα and CMAI scores at baseline and following nabilone treatment.
Measured: Is TNFα associated with CMAI scores at baseline or with change in CMAI scores after 6-weeks of nabilone treatment (i.e. between Baseline and Outcome Assessments)?
4-hydroxynonenal (4-HNE)
Examine the relationship between 4-HNE and CMAI scores at baseline and following nabilone treatment.
Measured: Is 4-HNE associated with CMAI scores at baseline or with change in CMAI scores after 6-weeks of nabilone treatment (i.e. between Baseline and Outcome Assessments)?
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2023
- Study start7 Mar 2023
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Why it stopped: Terminated due to slow recruitment: only 3 randomized in 2 years. Eligible population overestimated and funding exhausted; PI deemed further recruitment unfeasible. No participants on treatment, no safety concerns. All sites are now closed.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Frontotemporal DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This is a multi-centre double blind, placebo-controlled randomized cross-over study comparing 6 weeks of nabilone treatment to 6 weeks of placebo with a 3-week washout between periods. The study will involve an established network of up to 8 FTD centres in Canada.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 3 participants (actual)
Sponsor and investigators
- Lead sponsor
- Simon Ducharme, MD
- Sponsor type
- University, hospital or other
- Collaborators
- Alzheimer's Drug Discovery Foundation
- Responsible party
- Sponsor-investigator, Simon Ducharme, MD, Douglas Mental Health University Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05742698
- Sponsor's protocol ID
- Nabilone-FTD
- Acronym
- Nabilone-FTD
- Status last verified
- Jul 2026
- First submitted
- 23 Nov 2022
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be accessed by members of this multisite research team only, and only de-identified, not individual participant data, will be available to the research team.